The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and ...

Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs.

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while ...

BioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed that 170 employees are ...

The FDA has approved two diagnostic devices that allow women to collect vaginal samples themselves for cervical cancer ...

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible ...

Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology ...

Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its ...

Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side ...

Novo Nordisk is coming for Roche’s Hemlibra. A phase 3 trial of the Danish drugmaker’s challenger to the blockbuster ...

What a time to be launching a new biotech focused on inflammation and immunology. | Immunology and inflammation-focused drug ...

Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart ...